Glioma is a diverse category of tumors originating from glial cells encompasses various subtypes, based on the specific type of glial cells involved. The most aggressive is glioblastoma multiforme (GBM), which stands as the predominant primary malignant tumor within the central nervous system in adults. Despite the application of treatment strategy, the median survival rate for GBM patients still hovers around 15 months. Oncolytic viruses (OVs) are artificially engineered viruses designed to selectively target and induce apoptosis in cancer cells. While clinical trials have demonstrated encouraging results with intratumoral OV injections for some cancers, applying this approach to GBM presents unique challenges. Here we elaborate on current trends in oncolytic viral therapy and their delivery methods. We delve into the various methods of delivering OVs for therapy, exploring their respective advantages and disadvantages and discussing how selecting the optimal delivery method can enhance the efficacy of this innovative treatment approach.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.virol.2024.110033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Insights into the different mechanisms of Autophagy and Apoptosis mediated by Morbilliviruses.
Virology
December 2024
Department of Microbiology, University of Delhi South Campus, New Delhi, 110021, India. Electronic address:
Article Synopsis
- Viruses, like morbilliviruses, are parasites that depend on host cells and have evolved to manipulate the immune system by altering host proteins involved in biological processes.
- Morbilliviruses can interfere with programmed cell death mechanisms, such as autophagy and apoptosis, either using autophagosomes to delay host defenses or triggering apoptosis to spread infection.
- Recent research on the interaction between these pathways opens up possibilities for using morbilliviruses in developing new therapeutic strategies.
Understanding the Interplay between oHSV and the Host Immune System: Implications for Therapeutic Oncolytic Virus Development.
Mol Ther
December 2024
Department of Biology, College of Science and Technology, North Carolina Agricultural and Technical State University, Greensboro, NC 27411, USA. Electronic address:
Oncolytic herpes simplex viruses (oHSV) preferentially replicate in cancer cells while inducing antitumor immunity, and thus, they are often referred to as in situ cancer vaccines. OHSV infection of tumors elicits diverse host immune responses comprising both innate and adaptive components. Although the innate/adaptive immune responses primarily target the tumor, they also contribute to antiviral immunity, limiting viral replication/oncolysis.
View Article and Find Full Text PDFOncolytic measles virus-induced cell killing in radio-resistant and drug-resistant nasopharyngeal carcinoma.
Malays J Pathol
December 2024
Universiti Tunku Abdul Rahman, M. Kandiah Faculty of Medicine and Health Sciences, Department of Pre-clinical Sciences, Bandar Sungai Long, 43000, Kajang, Selangor, Malaysia.
Introduction: The current first-line therapy for nasopharyngeal carcinoma (NPC) is often associated with long-term complications. Oncolytic measles virus (MV) therapy offers a promising alternative to cancer therapy. This study aims to investigate the efficacy of MV in killing NPC cells in vitro, both with or without resistance to radiation and drug therapy.
View Article and Find Full Text PDFVLDLR mediates Semliki Forest virus neuroinvasion through the blood-cerebrospinal fluid barrier.
Nat Commun
December 2024
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Semliki Forest virus (SFV) is a neuropathogenic alphavirus which is of interest both as a model neurotropic alphavirus and as an oncolytic virus with proven potency in preclinical cancer models. In laboratory mice, peripherally administered SFV infiltrates the central nervous system (CNS) and causes encephalitis of varying severity. The route of SFV CNS entrance is poorly understood but has been considered to occur through the blood-brain barrier.
View Article and Find Full Text PDFHerpes Simplex Oncolytic Viral Therapy for Malignant Glioma and Mechanisms of Delivery.
World Neurosurg
December 2024
Department of Neurological Surgery, the University of Alabama at Birmingham, Birmingham, AL, USA.
The authors present a comprehensive review on the history and development of oncolytic herpes simplex viral therapies for malignant glioma with a focus on mechanisms of delivery in prior and ongoing clinical trials. This review highlights the advancements made with regard to delivering these therapies to a highly complex immunologic environment in the setting of the blood brain and blood tumor barrier in a safe and effective manner.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!